Nobias Therapeutics Joins NVIDIA Inception Program for Startups
MOUNTAIN VIEW, Calif. and PHILADELPHIA, April 16, 2024 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to discover advanced therapeutics, today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
- Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to discover advanced therapeutics, today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
- MOUNTAIN VIEW, Calif. and PHILADELPHIA, April 16, 2024 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a biotechnology company pioneering artificial intelligence (AI)-based deep phenotyping techniques to discover advanced therapeutics, today announced it has joined NVIDIA Inception , a program that nurtures startups revolutionizing industries with technological advancements.
- "Nobias has joined NVIDIA Inception to help further advance our capabilities to develop novel therapeutics for patients who would otherwise have limited or minimal available treatment options," said Sam Inala, Vice President of Engineering.
- "Accessing NVIDIA Deep Learning Institute workshops and courses, in addition to preferred pricing on essential technologies such as NVIDIA GPUs, will help drive the growth of Nobias and the Nobias Workbench™.